Title : Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.

Pub. Date : 2012 Jan 10

PMID : 21930168






9 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A targetable, heparin-triggered release system for tissue plasminogen activator (tPA) was designed to prevent the excessive "lytic" state associated with the current tPA therapy for acute thrombotic conditions, such as myocardial infarction (MI). Heparin chromosome 20 open reading frame 181 Homo sapiens
2 A targetable, heparin-triggered release system for tissue plasminogen activator (tPA) was designed to prevent the excessive "lytic" state associated with the current tPA therapy for acute thrombotic conditions, such as myocardial infarction (MI). Heparin chromosome 20 open reading frame 181 Homo sapiens
3 A targetable, heparin-triggered release system for tissue plasminogen activator (tPA) was designed to prevent the excessive "lytic" state associated with the current tPA therapy for acute thrombotic conditions, such as myocardial infarction (MI). Heparin chromosome 20 open reading frame 181 Homo sapiens
4 The strategy is, upon target accumulation, to trigger tPA release from a prodrug construct by a usual heparin dose. Heparin chromosome 20 open reading frame 181 Homo sapiens
5 A relatively inactive form of tPA was constructed by conjugating tPA with low-molecular weight heparin followed by complexation with albumin-protamine conjugate, termed "camouflage". Heparin chromosome 20 open reading frame 181 Homo sapiens
6 A relatively inactive form of tPA was constructed by conjugating tPA with low-molecular weight heparin followed by complexation with albumin-protamine conjugate, termed "camouflage". Heparin chromosome 20 open reading frame 181 Homo sapiens
7 The prodrug construct of tPA significantly masked the enzymatic activity, which was fully recovered upon heparin addition. Heparin chromosome 20 open reading frame 181 Homo sapiens
8 The camouflaged tPA was stable in human blood for at least 30min and was able to trigger enzyme activation in vitro at heparin level of 0.4U/mL. Heparin chromosome 20 open reading frame 181 Homo sapiens
9 This proof-of-principle study suggests that the activity of the tPA prodrug construct can be triggered at the thrombus site at therapeutic heparin concentration conjunctively used for MI with reduced bleeding risk. Heparin chromosome 20 open reading frame 181 Homo sapiens